

Miércoles 25	
15.45-16.00	INAUGURACIÓN
16.00-16.30	<p>SESIÓN DOCENTE</p> <p>IN BETWEEN THE TOP-DOWN AND BOTTOM-UP APPROACHES IN BUILDING PREDICTIVE PHARMACOKINETIC MODELS Iñaki F. Trocóniz, Universidad de Navarra</p>
16.30-17.15	<p>MODELING AND SIMULATION IN DRUG DEVELOPMENT. PRECLINICAL M&S (I)</p> <p>PBPK MODELING AND QUANTITATIVE STRUCTURE-PROPERTY RELATIONSHIPS TO PREDICT DRUG DELIVERY TO THE BRAIN Bárbara Sánchez-Dengra, Universidad Miguel Hernández</p> <p>PRECLINICAL CHARACTERIZATION OF PLASMA PROTEIN AND TISSUE BINDING OF AMIODARONE USING A POPULATION APPROACH Karine Rodriguez-Fernandez, Universidad de Valencia</p> <p>IMPLEMENTING A PHARMACOKINETIC MODEL FOR THE EVALUATION OF DRUG RELEASE FROM COATED MATRIX TABLETS Roberto Arévalo-Pérez, Universidad de Salamanca</p>
17.15-17.30	Pausa
17.30-18.15	<p>MODELING AND SIMULATION IN DRUG DEVELOPMENT. PRECLINICAL M&S (II)</p> <p>PHARMACODYNAMIC MODELLING AND SIMULATION OF AMPHOTERICIN B TIME-KILL CURVES AGAINST CANDIDA AURIS Unai Caballero, Universidad del País Vasco UPV/EHU</p> <p>PHYSIOLOGICALLY-BASED PHARMACOKINETIC/PHARMACODYNAMIC MODEL OF MBQ-167 TO PREDICT TUMOR GROWTH INHIBITION IN MICE Javier Reig-López, Universidad de Valencia</p> <p>MECHANISM-BASED CHARACTERIZATION OF COMBINATION TREATMENTS IN IMMUNONCOLOGY Aymara Sancho Araiz, Universidad de Navarra</p>
18.15-18.30	Pausa
18.30-19.00	<p>CLINICAL APPLICATIONS OF POPULATION PHARMACOKINETIC MODELS (I)</p> <p>DEVELOPMENT OF A PHARMACOKINETIC MODEL TO ADJUST INTRADUODENAL ADMINISTRATION IN HUMANS. Alejandro Ruiz-Picazo, Universidad Miguel Hernández</p> <p>APPLICATION OF A DUAL PBPK-POPPK MODEL BASED APPROACH ACROSS THE AGE-POPULATION OF ADULTS USING BILASTINE AS A PROBE DRUG Valentina Lo Re, Universidad del País Vasco UPV/EHU, Dynakin S.L.</p>

Jueves 26	
16.00-16.45	<p>CLINICAL APPLICATIONS OF POPULATION PHARMACOKINETIC MODELS (II)</p> <p>EVALUATION OF THE PREDICTIVE PERFORMANCE OF TWO POPULATION PHARMACOKINETIC MODELS OF VEDOLIZUMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE Silvia Márquez-Megías, Universidad Miguel Hernández</p> <p>POPULATION PHARMACOKINETIC MODEL OF CEFTRIAXONE IN CRITICALLY ILL PATIENTS WITH SEPTIC SHOCK AND CONTINUOUS VENO-VENOUS HEMODIAFILTRATION Carla Bastida, Universidad de Barcelona</p> <p>POPULATION PHARMACOKINETIC MODEL OF LEVETIRACETAM IN CRITICALLY ILL PATIENTS: ARE WE UNDERDOSING OUR PATIENTS? Idoia, Bilbao-Meseguer, Universidad del País Vasco UPV/EHU</p>
16.45-17.00	Pausa
17.00-17.30	<p>CLINICAL APPLICATIONS OF PHARMACODYNAMIC MODELING (I)</p> <p>MODELING CARDIAC EFFECTS OF INVESTIGATIONAL COVID-19 TREATMENTS Itziar Irurzun-Arana, Icahn School of Medicine at Mount Sinai, New York</p> <p>ASSOCIATION BETWEEN HETEROGENEITY OF INDIVIDUAL TUMOR LESIONS AND OVERALL SURVIVAL ASSESSED BY MACHINE LEARNING IN FOUR METASTATIC COLORECTAL CANCER CLINICAL STUDIES Diego Vera-Yunca, Universidad de Navarra, Merck Institute for Pharmacometrics, Instituto de Investigación Sanitaria de Navarra IdiSNA</p>
17.30-18.00	<p>CLINICAL APPLICATIONS OF PHARMACODYNAMIC MODELING (II)</p> <p>PHARMACODYNAMIC MODELLING OF MOVEMENT RESPONSE AFTER NOXIOUS STIMULUS IN PATIENTS UNDERGOING SURGERY Nicolás Marco-Ariño, Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra IdiSNA</p> <p>QUANTITATIVE ASSESSMENT OF THE EXPOSURE-EFFICACY RELATIONSHIP USING MARKOVIAN ELEMENTS IN GAUCHER PATIENTS Victor Mangas Sanjuan, Universidad de Valencia, Interuniversity Institute of Recognition Research Molecular and Technological Development</p>
18.00-18.15	Pausa
18.15-18.45	<p>PONENCIA</p> <p>POPULATION PHARMACOKINETICS AND INTEGRATED EXPOSURE-RESPONSE ANALYSIS OF EFFICACY AND SAFETY WITH LURBINECTEDIN TO SUPPORT THE DOSE REGIMEN IN SMALL CELL LUNG CANCER Carlos Fernández Teruel,</p>
18.45-19.00	ENTREGA DE PREMIOS Y CLAUSURA
19.00-20.00	ASAMBLEA